The Impact of Young and/or Exercised Blood Plasma Transfusions in Individuals With Neurodegenerative Conditions:...

The prevalence of neurodegenerative conditions is expected to continue to rise, with current treatments largely focused on the management of symptoms and not disease progression. Exercise is a therapy that has significant favorable effects on several of the modifiable risk factors that influence the development/progression of some neurodegenerative conditions. However, there are significant barriers to exercise for this population, warranting consideration of alternative or adjunct therapies. Blood plasma transfusion is an emerging nonpharmaceutical/nonexercise therapy that may have positive benefits on people and animal models with neurodegenerative conditions.

The aim of this study was to investigate and synthesize the literature on the impacts of young or exercised blood plasma transfusions in people and animal models with neurodegenerative conditions.

We will include studies that have explored the impacts of young or exercised blood plasma transfusions in adults or animal models with neurodegenerative conditions. PubMed Central, MEDLINE, Cochrane Database of Systematic Reviews, Scopus, ProQuest, SPORTDiscus, PROSPERO, and multiple unpublished sources, including book chapters, conference papers, and theses, will be searched to include literature from January 2004 to May 2024, written in English. Studies will be screened by 2 independent reviewers; a third reviewer will be used to resolve any conflicts. Data will be extracted into a modified charting tool and will be presented in a graphical or tabular format combined with the appropriate narration.

As of June 2024, the literature search has been completed. After searching listed databases, 3646 citations and 13 gray literature studies were identified, of which 1432 duplicates were removed.

To the best of our knowledge, this study will be the first study with the aim of investigating the literature on the impacts of young or exercised blood plasma transfusions in individuals with neurodegenerative conditions.

DERR1-10.2196/65935.